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Introduction
The number of end-stage renal disease (ESRD) patients 
requiring dialysis treatment has been rapidly increasing 
worldwide over the past few decades. Korea is one of the 
countries with the highest increase in incidence (120%, 
from 2000/2001 to 2012/2013) and prevalence of ESRD 
(from 585 per million in 2000/2001 to 1,442 per million in 
2012/2013) [1]. 
Most ESRD patients choose between hemodialysis (HD) 
and peritoneal dialysis (PD) at initiation of renal replace-
ment therapy. It is crucial to address which modality is a 
better option for long-term mortality and morbidity out-
comes in ESRD patients. Multiple studies have been con-
ducted to investigate these issues, but the results were 
not conclusive [2]. In Korea, we reported that overall 
mortality rate and incidence of cardiovascular events are 
higher in incident PD patients than in HD patients [3,4].
Short-term PD patient survival rate is generally consid-
ered superior to that of HD, whereas long-term PD sur-
vival is inferior or comparable to that of HD. Although it 
is an older report, the survival rate in US PD patients was 
86.8% at 1 year and only 11.3% at 10 years [5]. In Korea, 
the survival rate in PD patients was 95.2% at 1 year and 
36.4% at 10 years in the 2014 annual report of the Korean 
ESRD registry [6]; however, there have been some reports 
suggesting improvements in PD patient survival that 
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order to reduce mortality risk.
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must be considered when selecting dialysis modality. 
Herein, we summarize recent global trends in PD pa-
tient survival. In addition, we aim to elucidate why pa-
tient survival is worse and cardiovascular events are more 
prevalent among PD patients than HD patients in Korea.
A global trend of improving PD patient survival
Recently, patient survival with PD as an initial treat-
ment modality has consistently improved worldwide: 
this improvement was the most dramatic in the US. From 
patients starting dialysis in 2000 to those starting in 2008, 
survival rates improved in both HD and PD patients. Of 
note, the extent of improvement was more prominent 
in PD patients. The 5-year survival rate of HD patients 
improved from 34.5% to 40.2%, while that of PD patients 
greatly improved from 37.3% to 50.3% [1]. Therefore, the 
higher death rate of PD compared to HD seems to be at 
least comparable or reversed since the late 2000s. Most 
recently, US PD patients have had a similar life expec-
tancy to that of HD patients [7]. The authors analyzed 
data from the US Renal Data System for secular trends in 
survival among patients treated with HD and PD on day 
90 of ESRD in three 3-year cohorts (1996-1998, 1999-
2001, and 2002-2004). Analysis revealed that there was 
a progressive attenuation in the higher risk of death in 
patients treated with PD in earlier cohorts. For the 2002-
2004 cohort, there was no significant difference in risk of 
death between HD and PD patients.
A similar situation exists in Canada. The survival superi-
ority of HD over PD was lost from an old cohort to a more 
recent one, with HD and PD showing equivalent outcomes 
[8]. This result was mainly associated with advancement in 
PD patient survival. The adjusted median life expectancy 
of HD and PD patients was 48.3 and 43.8 months in the 
1991-1995 cohort period, respectively, while it was 51.7 
and 50.8 months in the 2001-2004 cohort period. 
In Australia and New Zealand, survival on dialysis ther-
apy has also improved despite increasing prevalence of 
comorbid conditions [9]. Home HD has been widely used 
in these two countries, and the proportion of patients us-
ing home HD at the end of 2014 was 9% in Australia and 
18% in New Zealand [10]. The survival rate was compared 
among in-center HD, home HD, and PD. Overall, there 
was a 25% lower adjusted mortality risk associated with 
dialysis inception during 2008 to 2012 compared to 1998 
to 2002. In addition, there was a 21% reduction in mortal-
ity for those on facility HD therapy, a 27% reduction for 
those on PD therapy, and a 49% reduction for those on 
home HD therapy. Therefore, survival improvement has 
been more prominent in home-based dialysis therapy 
compared to facility HD.
A similar phenomenon is seen in Brazilian PD patients. 
A comparison of outcomes according to the era of dialysis 
initiation was performed in a nationwide PD cohort [11]. 
Although PD patients recently had more comorbidities 
including diabetes mellitus (DM), patient survival im-
proved along all study periods. Compared to 2005/2006, 
patients starting in 2007/2008 had a relative risk reduc-
tion of 0.83, and those starting in 2009/2010 had a relative 
risk reduction of 0.69.
Although there has been no official report on temporal 
changes in patient survival including all European PD 
patients, there is scattered evidence in some countries. 
A cooperative study of Spanish PD registries showed that 
annual mortality was gradually decreasing, despite sig-
nificant regional differences [12]. In addition, one report 
showed that Italian PD patient survival significantly im-
proved over 30 years [13]. 
Recently, Hong Kong has experienced a situation dis-
tinct from that of global trends. The annual mortality rate 
of PD patients in 2000 was 26%, which was much lower 
in 2011 at 15% [14]. However, their 5-year patient survival 
was surprisingly found to be lower in the 2002-2006 co-
hort compared to the 1997-2001 cohort. The possible 
reasons include demographic differences between the 
two cohorts. Patients were older and the proportion of 
patients with diabetes or hypertension was also higher 
in the more recent cohort. Hong Kong is one of the most 
developed countries in terms of PD patient care; thus, the 
small change in patient characteristics could have signifi-
cant effects on patient outcomes.
In almost all countries, patients starting PD have more 
unfavorable baseline characteristics, which may translate 
to worse survival; however, the survival rate of patients 
starting PD has gradually and significantly improved, 
likely due to advancements in standard PD patient care. 
Comparison of PD patient survival between Korea 
and other countries 
Ethnic diversity and the heterogeneity of patient char-
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acteristics between those being treated with HD and PD 
at initiation of dialysis therapy are fundamental problems 
that make it difficult to draw conclusions regarding mor-
tality. Although some cardiovascular morbidities such as 
myocardial infarction (MI) and congestive heart failure 
(CHF) are more prevalent in PD patients in Korea at the 
initiation of dialysis therapy, patients on PD are gener-
ally younger and have fewer comorbidities than those on 
HD [4]. In the US, PD patients are younger and healthier, 
whereas in Australia and New Zealand, PD patients are 
older and more commonly have diabetes, coronary artery 
disease (CAD), cerebrovascular accidents, and peripheral 
vascular disease [15]. On the contrary, in Taiwan, no defi-
nite differences were found in age, proportion of patients 
with diabetes and cardiovascular disease, and severity of 
illness as measured by the Charlson Comorbidity Index 
score between patients with HD and PD [16]. 
Differences in baseline characteristics are affected by 
various factors. First, patient-related factors such as life-
style, economic status, predialysis education level, ability 
to perform self-care, and the availability of familial sup-
port are major determinants [17,18]. Social factors such 
as local cost barriers and reimbursement systems can 
also influence whether HD or PD is favored, which has a 
substantial impact on initial choice of modality [19,20]. 
Modality availability and physician preference also play 
considerable roles. 
Despite these differences, several common points can 
be deduced from previous studies regarding mortal-
ity based on dialysis modality: (1) PD is associated with 
equivalent or better survival among non-DM patients 
and younger DM patients in the US, Canada, and Den-
mark; (2) the relative risk of death from PD versus HD 
varies with time on dialysis treatment—PD is usually as-
sociated with better survival during the first 1-2 years, 
and results vary thereafter; (3) in patients with cardiac 
comorbidities (CAD or CHF), the death risk of PD pa-
tients is higher than that of HD patients [2,21-23]. 
However, our analysis of nationwide data that included 
more than 32,000 patients suggested that these findings 
are not necessarily valid in Korea. After controlling for 
baseline differences in demographic data and comor-
bidities between HD and PD patients using propensity 
score matching (7,049 patients for each modality), PD 
use was associated with a 20% higher mortality than HD 
use when used as the first modality. The inferiority of 
PD begins as early as 6 months after initiating dialysis 
therapy [4]. This trend was also evident in major cardio-
vascular outcomes in incident dialysis patients. Although 
hemorrhagic stroke was more frequently seen in HD than 
PD patients, the patients on PD had 29% and 18% higher 
risks of non-fatal MI and of the need for target vessel re-
vascularization, respectively, than patients on HD [3]. 
Recent trends identified by inter-modality comparisons 
have indicated that, although PD use is declining, patient 
survival with PD as an initial modality has consistently 
improved in the US, Canada, and Europe and has be-
come at least comparable or even superior to that of HD 
in recent years [7,8,24]. Korea is not an exception regard-
ing recent improvements in PD-related outcomes. 
In the Korean Society of Nephrology (KSN)-ESRD reg-
istry, there was significant improvement in long-term 
survival in both HD and PD patients. The five-year sur-
vival rate of HD patients improved from 52% in the 2005 
report to 71% in the 2014 report, while that of PD patients 
greatly improved from 29% to 66% during the same pe-
riod [6]. In addition, compared to patients initiating PD 
therapy during 1981-1992, those initiating therapy dur-
ing 1992-2005 had 32% and 35% decreases in the risk of 
death and technique failure, respectively [25]. A similar 
trend was also observed in a more recent cohort in Korea: 
there was significant improvement in the survival rate of 
incident PD patients during a relatively short interval be-
tween 2005 and 2008 [26]. After adjusting for confound-
ing variables, incident dialysis patients in 2008, including 
both HD and PD patients, had an 18% lower risk of death 
compared to those starting dialysis in 2005. This risk re-
duction was more prominent in PD patients than in HD 
patients. 
Furthermore, it is likely that the survival rate of PD pa-
tients improved greatly after 2008 in Korea. Analysis of a 
prospective observational cohort of 31 Korean dialysis 
centers with patients who started dialysis from 2008 to 
2011 revealed that the crude mortality rate was 78.5 per 
1,000 patient-years, and patients on PD had a 51% lower 
risk of death compared to those on HD [27]. This is a 
significantly lower value compared with 116 per 1,000 pa-
tient-years in all Korean incident ESRD patients initiating 
dialysis from 2005 to 2008 [3]. Therefore, we assume that 
PD patient survival in Korea has dynamically improved 
recently. 
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 Towards better PD patient survival in Korea 
Although the exact reason why Korean PD patients 
have worse outcomes is not currently clear, there are 
some potential explanations. First, as mentioned above, 
two large-scale studies based on the database from the 
Center for Medicare and Medicaid Services (CMS) and 
the United States Renal Data System (USRDS) revealed 
that incident ESRD patients with preexisting CAD or CHF 
might not be optimal candidates for PD. Adjusted mor-
tality risks were significantly higher in patients with CAD 
or CHF when initiating treatment with PD than with HD 
[21,22]. These findings directly opposed the widely ac-
cepted assumption that PD may have advantages over 
HD in cardiovascularly compromised patients in such a 
way that PD enables them to maintain more stable levels 
of blood pressure, volume status, electrolyte balance, and 
uremic toxins compared to HD [28-31]. In addition, oth-
er studies have also provided a basis to explain the dis-
advantage of PD in atherogenesis. Patients with PD had 
higher levels of total cholesterol, low-density lipoprotein-
cholesterol, and lipoprotein(a) along with lower levels of 
high-density lipoprotein-cholesterol compared to those 
with HD [32]. Elevated levels of sympathetic activity and 
asymmetric dimethylarginine (ADMA), a potential in-
ducer of endothelial dysfunction, were also reported in 
PD patients compared to those with HD [33]. Moreover, 
the chronic volume overload frequently encountered in 
PD patients may also create greater susceptibility to ad-
verse cardiac remodeling than in HD patients [34]. 
We also found that previous history of MI or CHF has 
a significant interaction with dialysis modality for major 
adverse cardiac and cerebrovascular events (MACCE; 
defined as a composite endpoint of all-cause mortality, 
non-fatal acute MI, percutaneous coronary interven-
tion, coronary artery bypass graft, and non-fatal stroke) 
in Korean incidnet dialysis patients (Fig. 1). In brief, in 
patients with preexisting MI and CHF, PD conferred a 
57% (relative risk [RR], 1.57; 95% confidence interval [CI], 
1.20-2.05) and 25% higher (RR, 1.25; 95% CI, 1.10-1.42) 
risk, respectively, of MACCE than HD [3]. There is further 
evidence supporting this hypothesis: the proportion of 
patients with CHF was significanly lower in those start-
ing PD in 2008 compared to those starting PD in 2005 
(17.2% in 2005 vs. 13.6% in 2008, P = 0.008). This could be 
directly associated with improved patient survival among 
patients starting PD in 2008 compared to those starting in 
2005.
Despite these evidence-based disadvantages of PD in 
cardiac-compromised patients, the practice pattern fa-
voring PD over HD when choosing initial dialysis modal-
ity for such patients is still observed in Korea. According 
to our study [4], the proportions of patients with preexist-
ing MI and CHF were significantly higher in PD patients 
than in HD patients (4.7% in PD vs. 3.3% in HD and 16.1% 
in PD vs. 14.3% in HD, respectively). Diabetes is another 
common condition associated with worse outcomes in 
patients on PD than in those on HD [2,23,35]. However, 
the percentage of diabetic patients was not significantly 
lower in patients initiating dialysis with PD than in those 
with HD.
Until 2008 in Korea, PD had been more frequently or 
at least comparably implemented in patients who were 
more likely to be adversely affected by PD than HD; this 
may lead to adverse outcomes from PD. This is in con-
trast to cases in Europe and the US where patients with 
CAD, CHF, and diabetes were at least evenly distributed 
between HD and PD or were more frequently assigned to 
With DM
Without DM
With a history of MI
Without a history of MI
With a history of CHF
Without a history of CHF
With a history of any CVD
Without a history of any CVD
P for interaction < 0.001
P for interaction = 0.001
P for interaction = 0.003
P for interaction < 0.001
0.0
PD better HD better
0.2 0.4 0.6 0.8 1.0 1.2 1.4 1.6 1.8 2.0
Figure 1. Comparison of adjusted 
relative risks of MACCE according to 
comorbidities. CHF, congestive heart 
failure; CVD, cardiovascular disease; 
DM, diabetes mellitus; HD, hemodialysis; 
MACCE, major adverse cardiac and cere-
brovascular events; MI, myocardial infarc-
tion; PD, peritoneal dialysis.
Kidney Res Clin Pract   Vol. 36, No. 1, March. 2017
26 www.krcp-ksn.org
HD than to PD [36,37]. 
When mortality and cardiovascular morbidities were 
compared as a study endpoint, we adjusted for baseline 
cardiac conditions and diabetic status. However, this 
adjustment is not perfect. It is not possible to control for 
all factors underlying overt cardiac diseases and diabetes 
that are intrinsically involved in the progression of car-
diovascular morbidities, which are the most important 
determinants of death in Korean dialysis patients [38]. 
Nevertheless, we do not think that all patients with CAD, 
CHF, or diabetes should avoid PD. Rather, we should 
identify baseline characteristics that do not increase risk 
or reduce risk and should refine them when those at high 
risk want to select PD as an initial dialysis modality.
Summary
A comparison of mortality and major cardiovascular 
events between HD and PD among dialysis patients in 
Korea revealed that PD was likely to be inferior to HD, 
with some exceptions in specific subgroups. However, 
this is not consistent with the results of other recent 
studies, and the results cannot be directly applied in 
practice. The discrepancy may be associated with dif-
ferences in practice-patterns as well as ethnicity-related 
patient characteristics, potential selection bias from non-
randomization, or other unmeasured factors [39]. With 
further analysis, we suggest that special attention should 
be given to patients with DM, CAD, or CHF when choos-
ing PD as the first dialysis modality. In addition, more 
meticulous patient care should be offered during the en-
tire duration of dialysis in high-risk PD patients in order 
to reduce mortality risk.
Recently, PD patient survival has significantly improved 
across countries around the world. However, their long-
term survival has not yet reached a sufficient level. Fur-
ther studies are required to investigate solutions for bet-
ter PD patient survival.
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